The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma

References

• Gil-Gil MJ, Mesia C, Rey M, Bruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013;7:123–35.
   PubMedGoogle Scholar
• Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003;30:10–4.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Burkhardt JK, Riina H, Shin BJ, et al. Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol 2011;17:286–95.
   PubMed Web of Science ®Google Scholar
• Deangelis L. Brain tumors. N Engl J Med. 2001;344:114–23.
   PubMed Web of Science ®Google Scholar
• Parney IF, Chang SM. Current chemotherapy for glioblastoma. Cancer J. 2003;9:149–56.
   PubMed Web of Science ®Google Scholar
• Becker KP, Yu J. Status quo–standard-of-care medical and radiation therapy for glioblastoma. Cancer J. 2012;18:12–9.
   PubMedGoogle Scholar
• Boockvar JA, Tsiouris AJ, Hofstetter CP, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. J Neurosurg 2011;114:624–32.
   PubMed Web of Science ®Google Scholar
• Figueiredo EG, Faria JW, Teixeira MJ. Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea]. Arq Neuropsiquiatr 2010;68:778–82.
   PubMed Web of Science ®Google Scholar
• Imbesi F, Marchioni E, Benericetti E, et al. A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas. Anticancer Res 2006;26:553–8.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14:1131–8.
   PubMed Web of Science ®Google Scholar
• Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol. 2008;6: 1–18.
   PubMed Web of Science ®Google Scholar
• Burkhardt JK, Riina H, Shin BJ, et al. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg 2012;77:130–4.
   PubMed Web of Science ®Google Scholar
• Bernacki J, Dobrowolska A, Nierwińska K, Małecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008;60:600–22.
   PubMed Web of Science ®Google Scholar
• Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998;42:1083–99.
   PubMed Web of Science ®Google Scholar
• Abacioglu U, Caglar HB, Yumuk PF, et al. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neurooncol 2011;103:585–93.
   PubMedGoogle Scholar
• Nishikawa R. Standard therapy for glioblastoma–a review of where we are. Neurol Med Chir (Tokyo) 2010;50:713–9.
   PubMed Web of Science ®Google Scholar
• Iacob G, Dinca EB, Davila C. Current data and strategy in glioblastoma multiforme. J Med Life 2009;2:386–93.
   PubMedGoogle Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733–40.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010;116: 5297–305.
   PubMed Web of Science ®Google Scholar
• Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 2005;103:2606–15.
   PubMed Web of Science ®Google Scholar
• Riina HA, Fraser JF, Fralin S, et al. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol 2009;8: 145–50.
   PubMedGoogle Scholar
• Cloughesy TF, Gobin YP, Black KL, et al. Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neurooncol 1997;35:121–31.
   PubMed Web of Science ®Google Scholar
• Chow KL, Gobin YP, Cloughesy T, et al. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. Am J Neuroradiol. 2000;21:471–8.
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Suri MFK, Khan J, et al. Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures. J Neurooncol 2001;51:151–8.
   PubMed Web of Science ®Google Scholar
• Kochii M, Kitamura I, Goto T, et al. Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma. J Neurooncol 2000;49: 63–70.
   PubMed Web of Science ®Google Scholar
• Silvani A, Eoli M, Salmaggi A, et al. Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. Neurol Sci 2002;23:219–24.
   PubMed Web of Science ®Google Scholar
• Chaudhry IH, O’Donovan DG, Brenchley PE, Reid H, Roberts IS. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001;39:409–15.
   PubMed Web of Science ®Google Scholar
• Jeon JY, Kovanlikaya I, Boockvar JA, et al. Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton magnetic resonance spectroscopic imaging study. Am J Neuroradiol 2012;33:2095–102.
   PubMed Web of Science ®Google Scholar
• Ashby LS, Shapiro WR. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neurooncol 2001;51:67–86.
   PubMed Web of Science ®Google Scholar
• Gobin YP, Cloughesy TF, Chow KL, et al. Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology 2001;218:724–32.
   PubMedGoogle Scholar
• Aoki T, Mizutani T, Nojima K, et al. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg 2010;112:50–6.
   PubMed Web of Science ®Google Scholar
• Reithmeier T, Graf E, Piroth T, et al. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer 2010;10:30.
   PubMed Web of Science ®Google Scholar
• Happold C, Roth P, Wick W, et al. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 2009;92:45–8.
   PubMedGoogle Scholar
• Glas M, Hundsberger T, Stuplich M, et al. Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. Oncology 2009;76:184–9.
   PubMedGoogle Scholar
• Borovski T, Beke P, van Tellingen O, et al. Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme. Oncogene 2012:1–10.
   Google Scholar
• Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488: 522–6.
   PubMed Web of Science ®Google Scholar
• Joshi S, Emala CW, Pile-Spellman J. Intra-arterial drug delivery: a concise review. J Neurosurg Anesthesiol 2007;19:111–9.
   PubMedGoogle Scholar
• Brandes AA, Tosoni A, Amistà P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 2004;63:1281–4.
   PubMed Web of Science ®Google Scholar
• Madajewicz S, Chowhan N, Tfayli A, et al. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. Cancer 2000;88:2350–6.
   PubMed Web of Science ®Google Scholar
• Simon JM, Noël G, Chiras J, et al. Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. Radiother Oncol 2003;67:45–51.
   PubMedGoogle Scholar